GeneMax Corp has added to its technology portfolio by expanding the license with the University of British Columbia in Vancouver, Canada. The added technology, developed under the Collaborative Research Agreement between GeneMax Corp and the University of British Columbia, is a method to identify novel tumor associated antigens produced by cancers. The identification of novel immune dominant antigens will enable the development of new cancer vaccines that can be patient specific as well as antigens generalized across differing cancer types and patient populations.

Ronald L. Handford, President & CEO of GeneMax, said, "This new technology will be an important tool for building the pipeline of products related to our lead product, which is a generalized immunotherapeutic for the treatment of a wide variety of carcinomas."